FORM 6-K<\/p>\n
\u00a0<\/p>\n
\nSECURITIES
\nAND EXCHANGE COMMISSION<\/p>\n
\nWashington,
\nD.C. 20549<\/p>\n
\n\u00a0<\/p>\n
\u00a0<\/p>\n
\nReport
\nof Foreign Issuer<\/p>\n
\u00a0<\/p>\n
\nPursuant
\nto Rule 13a-16 or 15d-16 of<\/p>\n
\nthe
\nSecurities Exchange Act of 1934<\/p>\n
\n\u00a0<\/p>\n
\nFor the
\nmonth of July 2026\u00a0<\/p>\n
\n\u00a0<\/p>\n
\nCommission
\nFile Number: 001-11960<\/p>\n
\n\u00a0<\/p>\n
AstraZeneca PLC<\/p>\n
\n\u00a0<\/p>\n
\n1
\nFrancis Crick Avenue<\/p>\n
\nCambridge
\nBiomedical Campus<\/p>\n
\nCambridge
\nCB2 0AA<\/p>\n
\nUnited
\nKingdom<\/p>\n
\n\u00a0<\/p>\n
\u00a0<\/p>\n
\nIndicate
\nby check mark whether the registrant files or will file annual
\nreports under cover of Form 20-F or Form 40-F.<\/p>\n
\u00a0<\/p>\n
\nForm
\n20-F X Form 40-F __<\/p>\n
\u00a0<\/p>\n
\nIndicate
\nby check mark if the registrant is submitting the Form 6-K in paper
\nas permitted by Regulation S-T Rule 101(b)(1):<\/p>\n
\u00a0<\/p>\n
\nIndicate
\nby check mark if the registrant is submitting the Form 6-K in paper
\nas permitted by Regulation S-T Rule 101(b)(7): ______<\/p>\n
\u00a0<\/p>\n
\nIndicate
\nby check mark whether the registrant by furnishing the information
\ncontained in this Form is also thereby furnishing the information
\nto the Commission pursuant to Rule 12g3-2(b) under the Securities
\nExchange Act of 1934.<\/p>\n
\u00a0<\/p>\n
\nYes __
\nNo X<\/p>\n
\u00a0<\/p>\n
\nIf
\n\u201cYes\u201d is marked, indicate below the file number
\nassigned to the Registrant in connection with Rule 12g3-2(b):
\n82-_____________<\/p>\n
\u00a0<\/p>\n
\n\u00a0<\/p>\n
\n\u00a0<\/p>\n
AstraZeneca PLC<\/p>\n
\n\u00a0<\/p>\n
\nINDEX
\nTO EXHIBITS<\/p>\n
\n\u00a0<\/p>\n
\u00a0<\/p>\n
\n1.<\/p>\n
Datroway approved
\nin EU for TNBC<\/p>\n
\n\u00a0<\/p>\n
\u00a0<\/p>\n
31 July 2026<\/p>\n
\u00a0<\/p>\n
Datroway\u00a0approved in the EU as only TROP2-directed
\nmedicine with overall survival benefit for the 1st-line treatment
\nof patients with metastatic TNBC who are not candidates for
\nimmunotherapy<\/p>\n
\u00a0<\/p>\n
Approval based on TROPION-Breast02 Phase III trial results where
\nAstraZeneca and Daiichi Sankyo’s Datroway showed a statistically
\nsignificant and clinically meaningful improvement for the dual
\nprimary endpoints of overall survival and progression-free
\nsurvival<\/p>\n
\u00a0<\/p>\n
Datroway now approved for two breast cancer indications in the
\nEU<\/p>\n
\u00a0<\/p>\n
AstraZeneca and Daiichi Sankyo’s\u00a0Datroway\u00a0(datopotamab deruxtecan) has been approved
\nin the European Union (EU) as monotherapy for the 1st-line
\ntreatment of adult patients with unresectable or metastatic
\ntriple-negative breast cancer (TNBC) who are not candidates for
\nPD-1\/PD-L1 inhibitor therapy.<\/p>\n
\u00a0<\/p>\n
The approval by the European Commission follows
\nthe\u00a0positive
\nopinion\u00a0of the Committee
\nfor Medicinal Products for Human Use of the European Medicines
\nAgency and is based on results from the TROPION-Breast02 Phase III
\ntrial which were\u00a0presented\u00a0at
\nthe 2025 European Society for Medical Oncology Congress and
\nsubsequently published in\u00a0Annals
\nof Oncology.<\/p>\n
\u00a0<\/p>\n
Giuseppe Curigliano, MD, PhD, Director of the Early Drug
\nDevelopment Division, European Institute of Oncology, Professor of
\nMedical Oncology, University of Milan, Italy and investigator for
\nthe TROPION-Breast02 trial, said:\u00a0“For people living with
\nmetastatic triple-negative breast cancer, every new treatment
\noption matters. Despite recent advances, more than two thirds of
\npatients are not candidates for immunotherapy and have had limited
\noptions beyond chemotherapy. In my practice, I see firsthand the
\ndevastating impact this aggressive disease has on patients and
\ntheir families. This approval of datopotamab deruxtecan provides a
\nnew treatment option for eligible patients and represents
\nmeaningful progress.”<\/p>\n
\u00a0<\/p>\n
Dave Fredrickson, Executive Vice President, Oncology Haematology
\nBusiness Unit, AstraZeneca, said: “Every year, more than 80,000
\npeople in Europe are diagnosed with triple-negative breast cancer,
\na disease that often affects younger women and has limited
\ntreatment options in the metastatic setting. Today’s approval
\nof\u00a0Datroway\u00a0brings an antibody drug conjugate\u00a0with
\na differentiated clinical profile underpinned by a strong survival
\nbenefit to\u00a0people with this aggressive
\ndisease.”<\/p>\n
\u00a0<\/p>\n
Ken Keller, Global Head of Oncology Business, and President and
\nCEO, Daiichi Sankyo, Inc, said: “With this
\napproval,\u00a0Datroway\u00a0is the only TROP2-directed antibody drug
\nconjugate approved in the EU that has demonstrated an overall
\nsurvival benefit in the 1st-line setting for the treatment of
\npatients with metastatic triple-negative breast cancer. We look
\nforward to bringing\u00a0Datroway\u00a0to patients in the EU as an additional
\ntreatment option with the potential to extend survival, reflecting
\nour commitment to advancing innovative medicines that address unmet
\nneeds for people living with cancer.”<\/p>\n
\u00a0<\/p>\n
In the trial, which included patients with metastatic TNBC who
\nexperienced early relapse following prior
\ntreatment,\u00a0Datroway\u00a0demonstrated a statistically significant and
\nclinically meaningful 5.0-month improvement in median overall
\nsurvival (OS) (hazard ratio [HR] 0.79; 95% confidence interval [CI]
\n0.64-0.98; p=0.0291) compared to chemotherapy as 1st-line treatment
\nin this patient population. Median OS was 23.7 months for patients
\ntreated with\u00a0Datroway\u00a0versus 18.7 months for those treated with
\nchemotherapy.\u00a0Datroway\u00a0reduced the risk of disease progression or
\ndeath by 43% compared to chemotherapy (HR 0.57; 95% CI 0.47-0.69;
\np<0.0001) as assessed by blinded independent central review
\n(BICR).\u00a0Datroway\u00a0was also associated with more robust
\ntreatment responses, including an objective response rate (ORR) of
\n62.5% compared to an ORR of 29.3% with
\nchemotherapy.1<\/p>\n
\u00a0<\/p>\n
The safety profile of\u00a0Datroway\u00a0in TROPION-Breast02 was consistent with
\nprevious clinical trials of\u00a0Datroway\u00a0in breast cancer.<\/p>\n
\u00a0<\/p>\n
Based on the results of TROPION-Breast02,\u00a0Datroway\u00a0has been included in the ESMO Clinical
\nPractice Guidelines as a Category IA 1st-line treatment option for
\npatients with metastatic TNBC who are not candidates for
\nimmunotherapy, and it is the preferred option for patients who have
\nrelapsed within six months of completing adjuvant
\ntherapy.2\u00a0In
\naddition,\u00a0Datroway\u00a0received a score of 4 out of 5 on the ESMO
\nMagnitude of Clinical Benefit Scale (ESMO-MCBS), recognising the
\nclinically meaningful benefit demonstrated in
\nTROPION-Breast02.3<\/p>\n
\u00a0<\/p>\n
Datroway\u00a0was\u00a0approved\u00a0in
\nthe US in May 2026 for the same indication. Additional reviews are
\nunderway in China and Japan, as well as Australia, Canada,
\nSingapore and Switzerland as part of Project
\nOrbis.<\/p>\n
\u00a0<\/p>\n
Datroway\u00a0is a specifically
\nengineered TROP2-directed DXd antibody drug conjugate discovered by
\nDaiichi Sankyo and being jointly developed and commercialised by
\nAstraZeneca and Daiichi Sankyo.<\/p>\n
\u00a0<\/p>\n
Notes<\/p>\n
\u00a0<\/p>\n
Triple-negative breast cancer<\/p>\n
TNBC accounts for approximately 15% of all breast cancer cases,
\nwith an estimated 365,000 diagnoses globally each
\nyear.4,5\u00a0In
\nEurope, there are an estimated 81,000 diagnoses of TNBC each
\nyear.4,6\u00a0TNBC
\nis diagnosed more frequently in younger and premenopausal women,
\nand is more prevalent in Black and Hispanic
\nwomen.7-9\u00a0Metastatic
\nTNBC is the most aggressive type of breast cancer and has one of
\nthe worst prognoses, with median OS of just 12 to 18 months and
\nonly about 15% of patients living five years following
\ndiagnosis.7,10,11<\/p>\n
\u00a0<\/p>\n
While some breast cancers may test positive for oestrogen
\nreceptors, progesterone receptors or overexpression of HER2, TNBC
\ntests negative for all three.7\u00a0Due
\nto its aggressive nature and absence of common breast cancer
\nreceptors, TNBC is characteristically difficult to
\ntreat.7\u00a0For
\npatients with metastatic disease with PD-L1 expressing tumours, the
\naddition of immunotherapy to chemotherapy has improved outcomes in
\nthe 1st-line setting.12,13\u00a0However,
\nfor approximately 70% of patients with metastatic TNBC who are not
\ncandidates for immunotherapy, chemotherapy was the standard
\n1st-line treatment.14<\/p>\n
\u00a0<\/p>\n
TROP2 is a protein broadly expressed in several solid tumours,
\nincluding TNBC.15\u00a0TROP2
\nis associated with increased tumour progression and poor survival
\nin patients with breast cancer.16,17<\/p>\n
\u00a0<\/p>\n
TROPION-Breast02<\/p>\n
TROPION-Breast02 is a global, multicentre, randomised, open-label
\nPhase III trial evaluating the efficacy and safety
\nof\u00a0Datroway\u00a0versus investigator’s choice of chemotherapy
\n(paclitaxel, nab-paclitaxel, capecitabine, carboplatin or eribulin)
\nin patients with previously untreated locally recurrent inoperable
\nor metastatic TNBC for whom immunotherapy was not an option. This
\nincluded patients whose tumours did not express PD-L1 as well as
\npatients with PD-L1 expressing tumours who could not receive
\nimmunotherapy due to prior exposure in early-stage disease,
\ncomorbidities or immunotherapy not being accessible in their
\ngeography. Enrolment included patients with de novo or recurrent
\ndisease, regardless of disease-free interval, and those with poor
\nprognostic factors such as stable brain
\nmetastases.<\/p>\n
\u00a0<\/p>\n
The dual primary endpoints of TROPION-Breast02 are OS and
\nprogression-free survival (PFS) as assessed by blinded independent
\ncentral review. Secondary endpoints include PFS as assessed by
\ninvestigator, ORR, duration of response, disease control rate,
\npharmacokinetics and safety.<\/p>\n
\u00a0<\/p>\n
TROPION-Breast02 enrolled 644 patients at sites in Africa, Asia,
\nEurope, North America and South America. For more information,
\nvisit\u00a0ClinicalTrials.gov.<\/p>\n
\u00a0<\/p>\n
Datroway<\/p>\n
Datroway\u00a0(datopotamab
\nderuxtecan; datopotamab deruxtecan-dlnk in the US only) is a
\nTROP2-directed ADC. Designed using Daiichi Sankyo’s proprietary DXd
\nADC Technology,\u00a0Datroway\u00a0is one of seven DXd ADCs in the oncology
\npipeline of Daiichi Sankyo, and one of the most advanced programmes
\nin AstraZeneca’s ADC scientific platform.\u00a0Datroway\u00a0is comprised of a humanised anti-TROP2 IgG1
\nmonoclonal antibody, developed in collaboration with Sapporo
\nMedical University, attached to a number of topoisomerase I
\ninhibitor payloads (an exatecan derivative, DXd) via
\ntetrapeptide-based cleavable linkers.<\/p>\n
\u00a0<\/p>\n
Datroway\u00a0is approved in
\nmore than 45 countries\/regions worldwide for the treatment of adult
\npatients with unresectable or metastatic HR-positive, HER2-negative
\n(IHC 0, IHC 1+ or IHC 2+\/ISH-) breast cancer who have received
\nprior endocrine-based therapy and chemotherapy for unresectable or
\nmetastatic disease based on results from
\nthe\u00a0TROPION-Breast01\u00a0trial.<\/p>\n
\u00a0<\/p>\n
Datroway\u00a0is approved in
\nmore than 30 countries\/regions worldwide for the treatment of adult
\npatients with unresectable or metastatic TNBC who are not
\ncandidates for PD-1\/PD-L1 inhibitor therapy based on the results
\nfrom the TROPION-Breast02 trial.\u00a0\u00a0<\/p>\n
\u00a0<\/p>\n
Datroway\u00a0is available in
\nthe US under accelerated approval for the treatment of adult
\npatients with locally advanced or
\nmetastatic\u00a0EGFR-mutated non-small cell lung cancer (NSCLC) who
\nhave received prior\u00a0EGFR-directed therapy and platinum-based chemotherapy
\nbased on results from the\u00a0TROPION-Lung05\u00a0and\u00a0TROPION-Lung01\u00a0trials.
\nContinued approval for this indication in the US may be contingent
\nupon verification and description of clinical benefit in a
\nconfirmatory trial.<\/p>\n
\u00a0<\/p>\n
Datroway\u00a0clinical development
\nprogramme<\/p>\n
A comprehensive global clinical development programme\u00a0is
\nunderway with more than 20 trials evaluating the efficacy and
\nsafety of\u00a0Datroway\u00a0across multiple cancers, including NSCLC,
\nTNBC and urothelial cancer.\u00a0The programme includes eight Phase
\nIII trials in lung cancer, five Phase III trials in breast cancer,
\nand one Phase II\/III trial in urothelial cancer
\nevaluating\u00a0Datroway\u00a0as a monotherapy and in combination with
\nother cancer treatments in various settings.<\/p>\n
\u00a0<\/p>\n
Daiichi Sankyo collaboration<\/p>\n
AstraZeneca and Daiichi Sankyo entered into a global collaboration
\nto jointly develop and commercialise\u00a0Enhertu\u00a0(trastuzumab deruxtecan)
\nin\u00a0March
\n2019\u00a0and\u00a0Datroway\u00a0in\u00a0July
\n2020,\u00a0except in Japan where Daiichi Sankyo
\nmaintains exclusive rights for each ADC. Daiichi Sankyo is
\nresponsible for the manufacturing and supply
\nof\u00a0Enhertu\u00a0and\u00a0Datroway.<\/p>\n
\u00a0<\/p>\n
AstraZeneca in breast cancer\u00a0<\/p>\n
Driven by a growing understanding of breast cancer biology,
\nAstraZeneca is challenging, and redefining, the current clinical
\nparadigm for how breast cancer is classified and treated to deliver
\neven more effective treatments to patients in need – with the bold
\nambition to one day eliminate breast cancer as a cause of
\ndeath.<\/p>\n
\u00a0<\/p>\n
AstraZeneca has a comprehensive portfolio of approved and promising
\ncompounds in development that leverage different mechanisms of
\naction to address the biologically diverse breast cancer tumour
\nenvironment.<\/p>\n
\u00a0<\/p>\n
With\u00a0Enhertu, AstraZeneca and Daiichi Sankyo are aiming to
\nimprove outcomes in previously treated HER2-positive, HER2-low and
\nHER2-ultralow metastatic breast cancer, and expanding its potential
\nin earlier lines of treatment and in new breast cancer
\nsettings.<\/p>\n
\u00a0<\/p>\n
In HR-positive breast cancer, AstraZeneca continues to improve
\noutcomes with foundational medicines\u00a0Faslodex\u00a0(fulvestrant) and\u00a0Zoladex\u00a0(goserelin) and aims to reshape the
\nHR-positive space with first-in-class AKT
\ninhibitor,\u00a0Truqap\u00a0(capivasertib), the TROP2-directed
\nADC,\u00a0Datroway, and next-generation oral
\nSERD,\u00a0Etcamah.<\/p>\n
\u00a0<\/p>\n
PARP inhibitor\u00a0Lynparza\u00a0(olaparib) is a targeted treatment option
\nthat has been studied in early and metastatic breast cancer
\npatients with an inherited\u00a0BRCA\u00a0mutation. AstraZeneca with MSD (Merck &
\nCo., Inc. in the US and Canada) continue to
\nresearch\u00a0Lynparza\u00a0in these settings. AstraZeneca is also
\nexploring the potential of saruparib, a potent and selective
\ninhibitor of PARP1, in combination with camizestrant
\nin\u00a0BRCA-mutated, HR-positive, HER2-negative advanced
\nbreast cancer.<\/p>\n
\u00a0<\/p>\n
To bring much-needed treatment options to patients with
\ntriple-negative breast cancer, an aggressive form of breast cancer,
\nAstraZeneca is collaborating with Daiichi Sankyo to evaluate the
\npotential of\u202fDatroway\u202falone and in combination with
\nimmunotherapy\u202fImfinzi\u00a0(durvalumab).\u202f<\/p>\n
\u00a0<\/p>\n
AstraZeneca in oncology<\/p>\n
AstraZeneca is leading a revolution in oncology with the ambition
\nto provide cures for cancer in every form, following the science to
\nunderstand cancer and all its complexities to discover, develop and
\ndeliver life-changing medicines to patients.<\/p>\n
\u00a0<\/p>\n
The Company’s focus is on some of the most challenging cancers. It
\nis through persistent innovation that AstraZeneca has built one of
\nthe most diverse portfolios and pipelines in the industry, with the
\npotential to catalyse changes in the practice of medicine and
\ntransform the patient experience.<\/p>\n
\u00a0<\/p>\n
AstraZeneca has the vision to redefine cancer care and, one day,
\neliminate cancer as a cause of death.<\/p>\n
\u00a0<\/p>\n
AstraZeneca<\/p>\n
AstraZeneca (LSE\/STO\/NYSE: AZN) is a global, science-led
\nbiopharmaceutical company that focuses on the discovery,
\ndevelopment, and commercialisation of prescription medicines in
\nOncology, Rare Disease, and BioPharmaceuticals, including
\nCardiovascular, Renal & Metabolism, and Respiratory &
\nImmunology. Based in Cambridge, UK, AstraZeneca’s innovative
\nmedicines are sold in more than 125 countries and used by millions
\nof patients worldwide. Please visit\u00a0astrazeneca.com\u00a0and
\nfollow the Company on Social Media\u00a0@AstraZeneca.<\/p>\n
\u00a0<\/p>\n
Contacts<\/p>\n
For details on how to contact the Investor Relations Team, please
\nclick\u00a0here.
\nFor Media contacts, click\u00a0here.<\/p>\n
\u00a0<\/p>\n
References<\/p>\n
\u00a0<\/p>\n
\n1.\u00a0\u00a0 Dent R, et al. Datopotamab
\nderuxtecan in patients with untreated, advanced triple-negative
\nbreast cancer (TROPION-Breast02): a randomised, open-label,
\ninternational, phase III trial.\u00a0Ann Oncol. Published online April 3,
\n2026<\/p>\n
\n2.\u00a0\u00a0\u00a0de Azambuja E, et
\nal.\u00a0Metastatic breast cancer: ESMO Clinical Practice Guideline
\nfor diagnosis, treatment and follow-up.\u00a0Ann Oncol. 2026.<\/p>\n
\n3.\u00a0\u00a0\u00a0ESMO. ESMO-MCBS Scorecard:
\nDatopotamab deruxtecan.\u00a0Available at:\u00a0https:\/\/www.esmo.org\/guidelines\/esmo-mcbs\/esmo-mcbs-for-solid-tumours\/esmo-mcbs-scorecards?scorecard=558.\u00a0Accessed
\nJuly 2026<\/p>\n
\n4.\u00a0\u00a0\u00a0O’Reilly D, et al. Overview of
\nRecent Advances in Metastatic Triple Negative Breast
\nCancer.\u00a0World J Clin
\nOncol.
\n2021;12(3):164-182.<\/p>\n
\n5.\u00a0\u00a0\u00a0World Health Organization.
\nGlobal Status Report on Cancer 2026. Available
\nat:\u00a0https:\/\/www.who.int\/publications\/i\/item\/9789240123977.\u00a0\u00a0Accessed
\nJuly 2026.<\/p>\n
\n6.\u00a0\u00a0 World Health Organization. Global
\nCancer Observatory: Europe. Available at:\u00a0https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/908-europe-fact-sheet.pdf.\u00a0Accessed
\nJuly 2026.<\/p>\n
\n7.\u00a0\u00a0 American Cancer Society.
\nTriple-Negative Breast Cancer. Available
\nat:\u00a0https:\/\/www.cancer.org\/cancer\/types\/breast-cancer\/about\/types-of-breast-cancer\/triple-negative.html.
\nAccessed July 2026.<\/p>\n
\n8.\u00a0\u00a0 Martinez ME, et al. Contribution of
\nClinical and Socioeconomic Factors to Differences in Breast Cancer
\nSubtype and Mortality Between Hispanic and Non-Hispanic White
\nWomen.\u00a0Breast Cancer Res
\nTreat.
\n2017;166(1):185-193.<\/p>\n
\n9.\u00a0\u00a0\u00a0Vargas L, et al. Risk Factors
\nfor Triple-Negative Breast Cancer Among Latina
\nWomen.\u00a0Cancer Epidemiol Biomarkers
\nPrev.\u00a02019;28(11):1771-1783.<\/p>\n
\n10.\u00a0\u00a0National Cancer Institute. SEER
\nCancer Stat Facts: Female Breast Cancer Subtypes. Available
\nat:\u00a0https:\/\/seer.cancer.gov\/statfacts\/html\/breast-subtypes.html.\u00a0Accessed
\nJuly 2026.<\/p>\n
\n11.\u00a0\u00a0Huppert LA, et al. Emerging
\nTreatment Strategies for Metastatic Triple-Negative Breast
\nCancer.\u00a0Ther Adv Med
\nOncol.
\n2022;14:1-25.<\/p>\n
\n12.\u00a0 Cortes J, et al. Pembrolizumab Plus
\nChemotherapy in Advanced Triple-Negative Breast
\nCancer.\u00a0N Engl J
\nMed.
\n2022;387:217-226.<\/p>\n
\n13.\u00a0 Geurts V, et al. Immunotherapy for
\nMetastatic Triple Negative Breast Cancer: Current Paradigm and
\nFuture Approaches.\u00a0Curr Treat Options
\nOncol. 2023;
\n24:628-643.<\/p>\n
\n14.\u00a0 Punie K, et al. Unmet Need for
\nPreviously Untreated Metastatic Triple-Negative Breast Cancer: a
\nReal-World Study of Patients Diagnosed from 2011 to 2022 in the
\nUnited States.\u00a0The
\nOncologist.
\n2025;30(3):oyaf034.<\/p>\n
\n15.\u00a0 Rossi V, et al.\u00a0Sacituzumab
\nGovitecan in Triple-Negative Breast Cancer: from Bench to Bedside,
\nand Back.\u00a0Front
\nImmunol.
\n2024;15:1447280.<\/p>\n
\n16.\u00a0 Lin H, et al. Significantly upregulated
\nTACSTD2 and Cyclin D1 Correlate with Poor Prognosis of Invasive
\nDuctal Breast Cancer.\u00a0Exp Mol
\nPathol.
\n2013:94(1):73-78.<\/p>\n
\n17.\u00a0\u00a0Goldenberg D, et al. The Emergence
\nof Trophoblast Cell-Surface Antigen 2 (TROP-2) as a Novel Cancer
\nTarget.\u00a0Oncotarget.\u00a02018;9(48):28989-29006.<\/p>\n
\u00a0<\/p>\n
\n\u00a0<\/p>\n
Matthew Bowden<\/p>\n
Company Secretary<\/p>\n
AstraZeneca PLC<\/p>\n
\u00a0<\/p>\n
\n\u00a0<\/p>\n
SIGNATURES<\/p>\n
\u00a0<\/p>\n
\nPursuant
\nto the requirements of the Securities Exchange Act of 1934, the
\nRegistrant has duly caused this report to be signed on its behalf
\nby the undersigned, thereunto duly authorized.<\/p>\n
\u00a0<\/p>\n
\n\u00a0<\/p>\n
\u00a0<\/p>\n
Date: 31 July 2026<\/p>\n
\u00a0<\/p>\n
\u00a0<\/p>\n
\nBy: \/s\/
\nMatthew Bowden<\/p>\n
\u00a0<\/p>\n
\nName:
\nMatthew Bowden<\/p>\n
\u00a0<\/p>\n
\nTitle:
\nCompany Secretary<\/p>\n","protected":false},"excerpt":{"rendered":"FORM 6-K \u00a0 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 \u00a0 \u00a0 Report of Foreign Issuer \u00a0 Pursuant…\n","protected":false},"author":2,"featured_media":72847,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[20662],"tags":[24358,11153,21721,40653,24174,29796,12166,36189,32435,40654],"class_list":["post-95439","post","type-post","status-publish","format-standard","has-post-thumbnail","category-astrazeneca","tag-antibody-drug-conjugate","tag-astrazeneca","tag-azn","tag-datopotamab-deruxtecan","tag-datroway","tag-eu-approval","tag-oncology","tag-overall-survival","tag-triple-negative-breast-cancer","tag-tropion-breast02"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@UnitedKingdom\/117021814142409930","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/95439","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/comments?post=95439"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/posts\/95439\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media\/72847"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/media?parent=95439"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/categories?post=95439"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/britain\/wp-json\/wp\/v2\/tags?post=95439"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}